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Severitya b s t r a c t
Background: Hypertriglyceridemia is the third most common cause of acute pancreatitis (AP). It has been
shown that hypertriglyceridemia aggravates the severity and related complications of AP; however,
detailed analyses of large cohorts are contradictory. Our aim was to investigate the dose-dependent
effect of hypertriglyceridemia on AP.
Methods: AP patients over 18 years old who underwent triglyceride measurement within the initial
three days were included into our cohort analysis from a prospective international, multicenter AP
registry operated by the Hungarian Pancreatic Study Group. Data on 716 AP cases were analyzed. Six
groups were created based on the highest triglyceride level (<1.7 mmol/l, 1.7e2.19 mmol/l, 2.2
e5.59 mmol/l, 5.6e11.29 mmol/l, 11.3e22.59 mmol/l, 22.6 mmol/l).
Results: Hypertriglyceridemia (1.7 mmol/l) presented in 30.6% of the patients and was significantly and
dose-dependently associated with younger age and male gender. In 7.7% of AP cases, hyper-
triglyceridemia was considered as a causative etiological factor (11.3 mmol/l); however, 43.6% of these
cases were associated with other etiologies (alcohol and biliary). Hypertriglyceridemia was significantly
and dose-dependently related to obesity and diabetes. The rates of local complications and organ failure
and maximum CRP level were significantly and dose-dependently raised by hypertriglyceridemia. Tri-
glyceride above 11.3 mmol/l was linked to a significantly higher incidence of moderately severe AP and
longer hospital stay, whereas triglyceride over 22.6 mmol/l was significantly associated with severe AP as
well.
Conclusion: Hypertriglyceridemia dose-dependently aggravates the severity and related complications of
AP. Diagnostic workup for hypertriglyceridemia requires better awareness regardless of the etiology of
AP.
© 2020 IAP and EPC. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Hypertriglyceridemia (HTG) affects 10e30% of the general adult
population [1,2]. Classifying HTG is complex; both genetic (pri-
mary) and environmental (secondary) factors can lead to an
elevated triglyceride (TG) level. In rare cases (2%), primary severe
HTG (TG  10 mmol/l) may arise as a result of autosomal recessive,
monogenic familial chylomicronemia syndrome (FCS, former Type
I). However, a majority of severe HTG cases are multifactorial and
have polygenic (mixed HTG, former Type V) determinants with
additional secondary factors. Mild-to-moderate HTG cases
(2e9.9 mmol/l TG) are similarly polygenic with complex genetic
susceptibility (former Type IV, Type IIB and Type III) [2e4]. As
regards environmental factors, alcohol, positive-energy balanced
diet, obesity, uncontrolled diabetes mellitus (DM), renal diseases,
pregnancy, hypothyroidism and medications (e.g., estrogen, reti-
noids, thiazides, and b-blockers) were shown to be responsible for a
raised TG level usually with the interaction of genetic susceptibility
[5,6].
HTG is the third most common cause of acute pancreatitis (AP),
and it is responsible for up to 15% of AP cases [7e9]. According to
the definition, the majority of experts agree that AP related to TG
above 5.6 mmol/l should be considered as suspected
hypertriglyceridemia-induced acute pancreatitis (HTG-AP) and AP
associated with TG over 11.3 mmol/l is confirmed as HTG-AP [4,10].
Importantly, the occurrence of AP increases with the increase in TG
level. There is a 5% possibility of developing AP if TG exceeds
11.3 mmol/l, and it rises to 10e20% if TG elevates over 22.6 mmol/l
[4]. HTG-AP is of great importance for several reasons: 1) it has
shown a rising incidence worldwide as a result of increasing
obesity-related dyslipidemia [11,12]; 2) it raises the risk of severe
AP and related complications [8,10,12e16]; and 3) there is no
evidence-based therapy for it [17e19].
We aimed to perform a cohort analysis for investigating the
dose-dependent effect of HTG on AP and providing data for further
prospective randomized clinical trials. In our current cohort study,
we show clear evidence that TG level dose-dependently worsens
the outcome of AP. The rate of local complications is significantlyhigher above 5.6 mmol/l, whereas significantly elevated organ
failure presents above 11.3 mmol/l TG level, strongly suggesting
that TG-lowering therapy can achieve a better outcome of AP at a
much lower TG level than we previously thought.
Methods
AP patients (n ¼ 1435) over 18 years old were enrolled in the
prospectively collected international, multicenter AP registry
operated by the Hungarian Pancreatic Study Group (HPSG) be-
tween 2012 and 2017. Post-hoc cohort analysis was performed on
716 AP cases who underwent TG measurement within 72 h from
admission. AP was diagnosed based on the International Associa-
tion of Pancreatology/American Pancreatic Association (IAP/APA)
and HPSG evidence-based guidelines [17,18]. Participating coun-
tries are shown in Sup. Fig. 1.
The threshold of the normal TG value was determined at
1.7 mmol/l [6]. Six groups were established based on the Endocrine
Society Clinical Practice Guideline and previously published clinical
data related to HTG-AP [4,6]: Group 1: <1.7 mmol/l; Group 2:
1.7e2.19 mmol/l; Group 3: 2.2e5.59 mmol/l; Group 4:
5.6e11.29 mmol/l; Group 5: 11.3e22.59 mmol/l; and Group 6:
22.6 mmol/l. To convert TG from mmol/l to mg/dl multiply by
88.57. In case of each variable, elevated TG groups (Groups 2e6)
were compared with the normal TG group (Group 1). TG categories
were collapsed to three groups (<1.7 mmol/l; 1.7e11.29 mmol/l;
11.3 mmol/l) for the analysis of organ failure because of the low
event number.
Seventy-three variables were collected from each AP case as
listed in Table S1. The analysis was performed on 42,655/52,268
available data. Local complications, organ failure and severity were
defined based on the revised Atlanta classification [20]. The 716
cases investigated have shown the same epidemiological andmajor
outcome distribution as the total cohort (1435 cases), demon-
strating that our patients’ population represents a normal AP
cohort (Sup. Fig. 2).
The registry received ethical permission from the Scientific and
Research Ethics Committee of the Medical Research Council
D. Mosztbacher et al. / Pancreatology 20 (2020) 608e616610(22254e1/2012/EKU) in 2012, and all the patients provided written
informed consent to participate. The study protocol conforms to the
ethical guidelines of the Declaration of Helsinki updated in 2013 as
reflected in a priori approval by the institution’s human research
committee.
Statistical analysis
Prior to analysis of the dataset, descriptive statistical tools were
used to describe the basic characteristics. Mean and standard error
of the mean were calculated for continuous variables, whereas the
incidence in each group was determined for categorical variables.
Depending on the distribution of the data, the independent Stu-
dent’s t-test or ManneWhitney U test was used to evaluate dif-
ferences between continuous parameters. The chi-square test or
Fisher’s exact test was conducted to analyze the relations between
the variables. We compared the confidence intervals (CI) of the
proportions to investigate differences in the incidence of moder-
ately severe cases between groups. A p-value less than 0.05 (0.05)
was determined as statistically significance. All analyses were
performed using IBM-SPSS Statistical Software Version 25 (IBM
Corporation, Armonk, NY, USA).
Results
In our cohort, 30.6% (n ¼ 219) of the patients presented withFig. 1. Epidemiology and etiology. A) Age distribution of acute pancreatitis (AP) cases in m
p ¼ 0.010). C) Gender distribution of triglyceride groups (e: p ¼ 0.002; f, g: p <
cholangiopancreatography.elevated TG level (1.7 mmol/l). HTG was significantly and dose-
dependently linked to younger age and male gender (Fig. 1AeC).
In 7.7% of AP cases (n ¼ 55), TG level was above 11.3 mmol/l, which
is considered as a causative etiological factor [6,10]. In 56.4% of
these cases, HTG-AP patients had no other etiology described;
however, raised TG level was also accompanied by alcohol in 38.2%
of these cases and by biliary etiology in 5.4%, showing that HTG-AP
is associated with other etiologies in a substantial number of cases
(Fig. 1D).
Data from patients’ medical history revealed that HTG is
significantly and dose-dependently linked to obesity and DM
(Fig. 2B and C); however, there is no relation to chronic pancreatitis
(CP) and the Charlson comorbidity index (CCI) [21] (Fig. 2A and D).
The amount of previous AP in the medical history was higher in the
HTG group compared to the normal TG group (Fig. 2A). General
symptoms of AP and physical examination on admission (inci-
dence, duration and intensity of pain, nausea, vomiting, abdominal
tenderness and guarding, and blood pressure) have not shown a
significant link to elevated TG level (Fig. 3A and B). However, HTG
was significantly related to increased heart rate (Fig. 3C). As regards
the laboratory parameters on admission showing significant dif-
ferences with HTG, amylase, lipase, sodium, and calcium were
associated inversely; however, glucose, C-reactive protein (CRP),
cholesterol, red blood cell count (RBC), hemoglobin, and hematocrit
were related parallel with TG level (Fig. 4). On admission laboratory
parameters consistent with cholestasis suggested that HTG is lessales and females. B) Age distribution of triglyceride (TG) groups (a, c, d: p¼<0.001; b:
0.001). D) Etiology. HTG ¼ hypertriglyceridemia; ERCP ¼ endoscopic retrograde
Fig. 2. Medical history of triglyceride groups. A) Acute pancreatitis (AP) and chronic pancreatitis (CP) in patients’ medical history (a: p ¼ 0.026; b: p ¼ 0.023). B) Obesity (body
mass index (BMI), kg/m2) (c: p ¼ 0.006; d: p ¼ 0.001). C) Diabetes mellitus in medical history (e: p ¼ 0.046; f: p ¼ 0.016; g: p ¼ 0.026; h: p < 0.001). D) Charlson comorbidity index
(CCI). N numbers (n) indicate the total number of cases in each triglyceride group.
Fig. 3. Symptoms and physical findings on admission in the different triglyceride (TG) groups. A) Incidence, duration before admission and intensity of pain. Nausea, vomiting,
abdominal tenderness and abdominal guarding (a: p ¼ 0.025; b: p ¼ 0.036). B) Systolic and diastolic blood pressures (Hgmm) (c: p ¼ 0.012). C) Heart rate (bpm) (d, e: p ¼ 0.010). N
numbers (n) indicate the total number of cases in each triglyceride group.
D. Mosztbacher et al. / Pancreatology 20 (2020) 608e616 611common in cases with biliary etiology. (Sup. Fig. 3). The parallel rise
in gamma-glutamyltransferase (gGT) and TG levels confirms that
alcohol consumption is linked to HTG (Sup. Fig. 3D). White bloodcell count (WBC), thrombocyte, lactate dehydrogenase (LDH), blood
urea nitrogen (BUN), creatinine, and potassium had no significant
relation to HTG (Sup. Fig. 4).
Fig. 4. Laboratory parameters on admission significantly associated with hypertriglyceridemia. A) Triglyceride groups [1e6]. B) Amylase (U/l) (a: p ¼ 0.036; b, c, e: p¼<0.001;
d: p ¼ 0.009). C) Lipase (U/l) (f: p ¼ 0.017; g: p ¼ 0.001). D) Sodium (mmol/l) (h, i: p¼<0.001; j: p ¼ 0.005). E) Calcium (mmol/l) (k: p ¼ 0.012). F) Glucose (mmol/l) (l, m: p¼<0.001).
G) C-reactive protein (CRP, mg/l) (n: p ¼ 0.021; o: p ¼ 0.014). H) Cholesterol (mmol/l) (p: p ¼ 0.008; q: p ¼ 0.006; r, s: p < 0.001). I) Red blood cell count (RBC, T/l) (t: p ¼ 0.017; u:
p ¼ 0.004) J) Hemoglobin (G/l) (v: p ¼ 0.008; w: p < 0.001; x: p ¼ 0.002). K) Hematocrit (%) (y: p ¼ 0.009; z: p ¼ 0.014). N numbers (n) indicate the total number of cases in each
triglyceride group.
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D. Mosztbacher et al. / Pancreatology 20 (2020) 608e616 613The rate of local complications, including peripancreatic fluid
collection, pancreatic necrosis and DM, was significantly and dose-
dependently increased with TG level (Fig. 5BeE); however,
pancreatic pseudocysts did not show significant differences be-
tween the investigated groups above 2.2 mmol/l (Fig. 5F). Organ
failure, including heart and renal failure, and maximum CRP level
were significantly and dose-dependently raised by TG level (Fig. 6B,
D-G); however maximum WBC has not shown any significant dif-
ferences by HTG (Fig. 6C).
As regards severity, TG level above 11.3 mmol/l was associated
with a significantly higher rate of moderately severe AP and longer
hospital stay, whereas TG level above 22.6 mmol/l was significantly
related to severe AP as well (Fig. 7A and B). Due to the low event
rate, the effect of HTG on mortality could not be determined
(Fig. 7A). Detailed values of charts and statistical parameters are
shown in Tables S2 and S3.
Plasmapheresis was carried out in 36.4% (20/55) of the HTG-AP
cases; 85% of these patients had an initial TG level higher than
22.6 mmol/l and the average TG level was 70.1 ± 10.0 mmol/l.
Discussion
HTG-AP has grown in incidence and importance. According to
the previously published literature [7,9], HTG is the third most
common cause of AP (7.7%). However, it seemsmore than likely that
the incidence of HTG-AP is higher than is usually recorded. The
prospective multicenter, international AP cohort run by the HPSG
revealed that TG measurement is performed in just 50% (716/1435)
of AP cases within the first three days from admission and most
probably this rate is even worse in centers which provide no data.
Furthermore, our data also confirmed additional etiological factors
(alcohol and biliary disease) besides HTG in 43.6% of HTG-AP cases
and showed a dose-dependent relation between obesity (body
mass index), pre-existing DM and HTG. These data also suggest a
higher incidence rate since physicians finding an etiological factor
behind AP usually stop further investigation. Our data are in
accordance with Scherer et al. who recommend that HTG-AP
should be suspected in the case of significant alcoholFig. 5. Local pancreatic complications in the different triglyceride groups. A) Triglyceride
collection (c: p ¼ 0.004; d: p < 0.001). D) Pancreatic necrosis (e: p ¼ 0.003; f: p < 0.001). E) D
pseudocyst (j: p ¼ 0.031). N numbers (n) indicate the total number of cases in each triglycconsumption, poorly controlled DM and metabolic syndrome,
including obesity [4]. Although our data clearly show that biliary
obstruction may be associated with HTG, serum TG was measured
in just 44.3% (266/601) of the biliary AP cases. Furthermore, in the
case of biliary AP, there is no recommendation for TGmeasurement.
Our data analysis confirmed results published by Zheng et al.
[12] and Zhu et al. [8] which show that HTG is significantly linked to
younger age and male gender. This is not surprising, since under-
lying genetic abnormalities behind HTG contribute to younger
manifestation and alcohol-related HTG affects male gender and
younger age more [3,4,22]. In contrast, biliary etiology is accom-
panied by a higher rate for female gender and older population
[3,23].
Diagnosing AP in the presence of HTG can be challenging due to
in vitro interference between plasma TG level above 5.6 mmol/l
(with grossly turbid plasma) and determination of amylase and
lipase activities [24,25]. Our data confirmed a significant reduction
of amylase and lipase levels with the elevation of TG. Furthermore,
case reports have been published by Singh et al. [26] and Sotello
et al. [27], presenting HTG-AP patients with normal amylase and
lipase levels.
Our analysis has shown that local complications and organ
failure were significantly increased by HTG, just as published in
previous reports and a recent meta-analysis by Kiss et al.
[10,13,15,28,29]. Nawaz et al. [30] confirmed that TG above
2.3 mmol/l is independently associated with persistent organ fail-
ure on a multivariate analysis controlling for age, gender, body
mass index, diabetes, and alcohol etiology, whereas Szentesi et al.
[31] revealed that hyperlipidemia was an independent predictive
factor for local complications and new-onset DM. Although we
could not confirm a significantly higher risk of pancreatic pseu-
docysts in the case of TG above 2.2 mmol/l, it is well known that
pseudocysts usually occur more than four weeks after the onset of
AP and the average hospital stay was 10.4 ± 0.3 days in our cohort
[20].
Based on our data analysis, severity of AP and length of hospi-
talizationwere significantly increased by HTG [8,10,12,13,29,30,32].
Navarro et al. [33] and Goyal et al. [34] also confirmed that HTGgroups [1e6]. B) Local pancreatic complications (a, b: p < 0.001). C) Peripancreatic fluid
iabetes mellitus as complication (g: p ¼ 0.004; h: p < 0.001; i: p ¼ 0.011). F) Pancreatic
eride group.
Fig. 6. Systemic inflammatory effect and organ failure in the different triglyceride groups. A) Triglyceride groups [1e6]. B) Maximum C-reactive protein (Max CRP, mg/l) (a, c:
p < 0.001; b: p ¼ 0.029). C)Maximumwhite blood cell count (Max WBC, G/l). D) Organ failure (d: p ¼ 0.001). E) Respiratory failure. F) Heart failure (e: p ¼ 0.007). G) Renal failure (f:
p ¼ 0.002). N numbers (n) indicate the total number of cases in each triglyceride group.
D. Mosztbacher et al. / Pancreatology 20 (2020) 608e616614aggravates the severity of AP compared to biliary and alcoholic
etiology, respectively. The underlying mechanism is clearly com-
plex. Unsaturated free fatty acids (UFAs) generated from TG areresponsible for cell injury by membrane lipid peroxidation, long-
lasting cytosolic Ca2þ elevation and mitochondrial damage
[35,36]. In the case of additional alcohol consumption, non-
Fig. 7. Outcomes in the different triglyceride (TG) groups. A) Length of hospitalization (LOH, day) and mortality (event n) (a: p ¼ 0.034; b: p ¼ 0.001). B) Severity (c: p ¼ 0.001; d:
p < 0.001). Moderately severe acute pancreatitis (AP) cases (Group 1: 22.6% (95% CI: 19%e26.6%); Group 5: 66.7% (95% CI: 38.4%e88.2%); Group 6: 47.4% (95% CI: 31.0%e64.2%)).
Severe AP cases (e: p ¼ 0.006). N numbers (n) indicate the total number of cases in each triglyceride group.
D. Mosztbacher et al. / Pancreatology 20 (2020) 608e616 615oxidative ethanol metabolites (fatty acid ethyl esters, FAEEs)
contribute to the persistent Ca2þ elevation and drop of ATP level
[37,38]. Besides, the raised plasma viscosity caused by hyper-
chylomicronemia leads to ischemia and acidosis in the pancreatic
capillaries [5]. This pathologic environment results in an early
trypsinogen activation and pancreatic lipase leakage, leading to
further free fatty acid (FFA) release and accumulation [5,35,39].
Moreover, UFAs bring about a systemic pro-inflammation by
increased mRNA production of tumor necrosis factor-alpha (TNF-a)
and neutrophil chemoattractants, thereby increasing the severity of
AP [36]. In our cohort, heart rate and maximum CRP were signifi-
cantly raised by HTG, confirming the systemic inflammatory effect
of relatively high TG level. In contrast, Pothoulakis et al. [40] and
Balachandra et al. [41] reported that HTG does not worsen severity.
Furthermore, Wang et al. showed that longer hospital stay was
associated with higher TG level, but the difference was not signif-
icant [29].
The overall mortality of AP is ~1% based on the literature [3,12]
and 1.5% in our cohort, but we could not perform a further sub-
group analysis because of the low event number. Zhu et al. [8] and
Deng et al. [42] confirmed that HTG-AP is accompanied by a
significantly higher rate of mortality among severe AP cases
compared to biliary AP and non-HTG etiology, respectively. How-
ever, Tai et al. [32] showed that mortality was similar in HTG-AP
and biliary AP groups in a general AP cohort.
In our cohort, plasmapheresis was carried out in 36.4% of the
HTG-AP cases. Although our data clearly suggest that the severity of
AP is significantly elevated above 11.3 mmol/l TG level, the average
TG level was 70.1 ± 10.0 mmol/l in patients with plasmapheresis
and 85% of these cases had a TG level over 22.6 mmol/l. We could
not state any further conclusion regarding the therapy because of
incomplete data and lack of randomization as a result of the cohort
feature of the dataset. Overall, in most cases, TG-lowering therapy,
such as plasmapheresis and glucose-heparin-insulin (GLU-HEP-
INS) administration, is performed above a TG level of 40 mmol/l. In
order to solve this unmet need, the HPSG has initiated a prospective
randomized clinical trial to investigate different lipid-lowering
therapies in AP [43].
Our study has several limitations. Although all data were
collected prospectively, all questions were raised retrospectively.
Cases were included into the analysis with TGmeasurement within
the first three days from admission, but unfortunately still just 50%
of the entire cohort met the inclusion criteria. We attempted to
minimize these limitations by comparing the epidemiological and
major outcome distributions of the data analyzed and the whole
cohort. We confirmed that the population under investigationrepresents a normal AP cohort.
Conclusion
Our results confirm that HTG dose-dependently increases the
complications and severity of AP and highlights the necessity of
better awareness of an accurate determination of causative and
influencing risk factors in AP regardless of the etiology. Our data
suggest that lipid-lowering therapymay be important clinically at a
much lower TG level than we previously thought.
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